@article{RECOVERY_Collaborative_Group-2023_200920,
title = {Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial},
author = {RECOVERY Collaborative Group},
month = {oct},
year = {2023},
abstract = {BackgroundEmpagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.},
pages = {905-914},
volume = {11},
issue = {12},
journal = {The Lancet Diabetes & Endocrinology},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S2213-8587(23)00253-X},
}
